Table 2.
Characteristics at follow-up for all 379 patients
| Months of follow-up, median(range) | 32(6-99) |
| Study endpoint, n(%) | |
| HCC | 44(12) |
| Liver Transplantation | 31(8) |
| Last imaging before death | 46(12) |
| Last imaging before loss to follow-up | 78(21) |
| Last imaging before end of study | 180(47) |
| Child class, n(%) | |
| A | 143(38) |
| B | 136(36) |
| C | 99(26) |
| MELD, median(range) | 14(6-54) |
| HCC Diagnostic Criteria, n(%) | |
| Biopsy | 13(30%) |
| Imaging | 30(68%) |
| AFP>1000 | 1(2%) |
| AJCC staging at diagnosis, n(%) | I |
| T1N0M0 | 20(45) |
| T2N0M0 | 19(43) |
| T2N1M0 | 1(2) |
| T3N1M0 | 2(4) |
| T4N1M1 | 1(2) |
| Undetermined | 1(2) |
| BCLC staging at diagnosis, n(%) | |
| A | 29(66) |
| B | 13(30) |
| C | 1(2) |
| Undetermined | 1(2) |
| 3 Year Kaplan-Meier cumulative HCC incidence, % | |
| Entire cohort | 10.4 |
| HCV patients | 12.2 |
| Viral cirrhosis | 12.0 |
| Non-viral cirrhosis | 5.1 |
| Asian | 13.1 |
| Non-Asian | 9.6 |
| Child A | 5.7 |
| Child B or C | 14.8 |
HCC, hepatocellular cardinoma; MELD, model for end-stage liver disease; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; HCV, hepatitis C virus